دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Screening for Dilated Cardiomyopathy in At-Risk First-Degree Relatives
Hanyu Ni, P HD, MPH,a,b Elizabeth Jordan, MMS C,a,b Daniel D. Kinnamon, P HD, a,b Jinwen Cao, MS, a,b Garrie J. Haas, MD, b,c Mark Hofmeyer, MD,d Evan Kransdorf, MD, PHD, e Gregory A. Ewald, MD, f Alanna A. Morris, MD, MSC ,g Anjali Owens, MD, h Brian Lowes, MD, P HD, i Douglas Stoller, MD, PHD, i W.H. Wilson Tang, MD,j Sonia Garg, MD, k Barry H. Trachtenberg, MD,l Palak Shah, MD, MS, m Salpy V. Pamboukian, MD,n Nancy K. Sweitzer, MD, PH D, o Matthew T. Wheeler, MD, PH D, p Jane E. Wilcox, MD, q Stuart Katz, MD, r Stephen Pan, MD, MS,s Javier Jimenez, MD, PH D, t Daniel P. Fishbein, MD,u Frank Smart, MD,v Jessica Wang, MD, w Stephen S. Gottlieb, MD, x Daniel P. Judge, MD,y Charles K. Moore, MD,z Gordon S. Huggins, MD,aa Ray E. Hershberger, MD
doi : 10.1016/j.jacc.2023.03.419
Volume 81, Issue 21, 30 May 2023, Pages 2059-2071
Cardiovascular screening is recommended for first-degree relatives (FDRs) of patients with dilated cardiomyopathy (DCM), but the yield of FDR screening is uncertain for DCM patients without known familial DCM, for non-White FDRs, or for DCM partial phenotypes of left ventricular enlargement (LVE) or left ventricular systolic dysfunction (LVSD).
Clinical Screening for Dilated Cardiomyopathy in At-Risk First-Degree Relatives: Who, When, and How?∗
Juan Pablo Kaski, BS C, MBBS, MD(R ES), a,b Douglas Cannie, MA, MBBS
doi : 10.1016/j.jacc.2023.04.001
Volume 81, Issue 21, 30 May 2023, Pages 2072-2074
Improved Outcomes After Pulmonary Valve Replacement in Repaired Tetralogy of Fallot
Jouke P. Bokma, MD, PHD, a Tal Geva, MD, b, * Lynn A. Sleeper, SC D, b Ji Hae Lee, BA, b Minmin Lu, MS,b Tehila Sompolinsky, MD,b Sonya V. Babu-Narayan, MB, BS, BSC , PH D, c Rachel M. Wald, MD, d Barbara J.M. Mulder, MD, PHD, a Anne Marie Valente, MD
doi : 10.1016/j.jacc.2023.02.052
Volume 81, Issue 21, 30 May 2023, Pages 2075-2085
The impact of pulmonary valve replacement (PVR) on major adverse clinical outcomes in patients with repaired tetralogy of Fallot (rTOF) is unknown.
Pulmonary Valve Replacement in Repaired Tetralogy of Fallot: Appropriate Timing Saves Lives∗
Jonathan N. Menachem, MD, a Alexander R. Opotowsky, MD, MMS C b
doi : 10.1016/j.jacc.2023.04.005
Volume 81, Issue 21, 30 May 2023, Pages 2086-2088
Procedure-Related Complications of Catheter Ablation for Atrial Fibrillation
Karim Benali, MD,a,b,c Paul Khairy, MD, PHD, a Nefissa Hammache, MD,d Adrian Petzl, MD, a Antoine Da Costa, MD, PH D, b Atul Verma, MD, e Jason G. Andrade, MD,a,f Laurent Macle, MD
doi : 10.1016/j.jacc.2023.03.418
Volume 81, Issue 21, 30 May 2023, Pages 2089-2099
Catheter ablation of atrial fibrillation (AF) is a commonly performed procedure. However, it is associated with potentially significant complications. Reported procedure–related complication rates are highly variable, depending in part on study design.
Atrial Fibrillation Ablation: Safety in Numbers∗
Kevin J. Ferrick, MD
doi : 10.1016/j.jacc.2023.04.002
Volume 81, Issue 21, 30 May 2023, Pages 2100-2102
The Inflation Reduction Act and Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Disease
Dhruv S. Kazi, MD, MS C, MS, a,b Colette DeJong, MD, c Randi Chen, MS, d Rishi K. Wadhera, MD, MS, a,b Chien-Wen Tseng, MD, MS, MPH
doi : 10.1016/j.jacc.2023.03.414
Volume 81, Issue 21, 30 May 2023, Pages 2103-2111
High out-of-pocket costs can impede access to guideline-directed cardiovascular drugs. The 2022 Inflation Reduction Act (IRA) will eliminate catastrophic coinsurance and cap annual out-of-pocket costs for Medicare Part D patients by 2025.
The Inflation Reduction Act Expands Prescription Drug Affordability: Decades in the Making∗
Jimmy Zheng, MD, MS, a Alexander T. Sandhu, MD, MS b
doi : 10.1016/j.jacc.2023.03.415
Volume 81, Issue 21, 30 May 2023, Pages 2112-2114
Management of Mechanical Prosthetic Heart Valve Thrombosis: JACC Review Topic of the Week
César E. Soria Jiménez, MD, a Alexander I. Papolos, MD,a,b Benjamin B. Kenigsberg, MD,a,b Itsik Ben-Dor, MD,c Lowell F. Satler, MD, c Ron Waksman, MD,c Jeffrey E. Cohen, MD, d Toby Rogers, MD, PHD
doi : 10.1016/j.jacc.2023.03.412
Volume 81, Issue 21, 30 May 2023, Pages 2115-2127
Mechanical prosthetic heart valves, though more durable than bioprostheses, are more thrombogenic and require lifelong anticoagulation. Mechanical valve dysfunction can be caused by 4 main phenomena: 1) thrombosis; 2) fibrotic pannus ingrowth; 3) degeneration; and 4) endocarditis.
Increased Risk of Thoracic Aortic Aneurysms With JAK2 V617F
Tetsushi Nakao, MD, PhD Zhi Yu, MB, PhD Caitlyn Vlasschaert, MD, MSc Md Mesbah Uddin, PhD Mark E. Lindsay, MD, PhD Patrick T. Ellinor, MD, PhD Benjamin L. Ebert, MD, PhD Alexander G. Bick, MD, PhD James P. Pirruccello, MD *Pradeep Natarajan, MD, MMSc
doi : 10.1016/j.jacc.2023.03.413
Volume 81, Issue 21, 30 May 2023, Pages 2128-2130
About Left Ventricular Filling Pressures in CTEPH
*Robert Naeije, MD
doi : 10.1016/j.jacc.2023.03.416
Volume 81, Issue 21, 30 May 2023, Page e181
Reply: About Left Ventricular Filling Pressures in CTEPH
Christian Gerges, MD, PhD *Irene M. Lang, MD
doi : 10.1016/j.jacc.2023.03.417
Volume 81, Issue 21, 30 May 2023, Page e183
